Department of Internal Medicine, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.
Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, The Netherlands.
Eur J Cancer Care (Engl). 2021 Nov;30(6):e13495. doi: 10.1111/ecc.13495. Epub 2021 Jul 26.
Screening for hepatitis B virus (HBV) before chemotherapy is recommended by international guidelines; still, the HBV screening rate is low, and patients remain at risk for HBV reactivation (HBVr). Because HBVr is a serious and preventable condition, we conducted a survey to evaluate the screening behaviour of oncologists in the Netherlands.
We conducted an anonymous digital survey by email to all practicing medical oncologists. The surveys were sent in two session, the first one in 2017 and the second one in 2019. Questions included HBV screening procedures, reasons for screening and experience with HBVr.
Among the 110 respondents, 29 (27%) followed a standardised protocol. Overall, 13 (12%) oncologists screened all patients, 76 (70%) only screened patients they considered as high risk and 19 (18%) did not screen anyone. Fourteen percent of the respondents experienced a HBVr in one of their patients.
This survey suggests that universal HBV screening is not common practice and usually patients considered as at risk for HBVr are screened, while this group is not always properly identified. Introduction of a national protocol for HBV screening and adjustment of the Dutch oncology guidelines might contribute to a reduction of HBVr during chemotherapy.
国际指南建议在化疗前筛查乙型肝炎病毒（HBV）；然而，HBV 的筛查率仍然很低，患者仍有发生 HBV 再激活（HBVr）的风险。由于 HBVr 是一种严重且可预防的疾病，我们进行了一项调查，以评估荷兰肿瘤学家的筛查行为。
我们通过电子邮件向所有执业肿瘤内科医生进行了匿名数字调查。调查分两期进行，第一期在 2017 年，第二期在 2019 年。问题包括 HBV 筛查程序、筛查原因和 HBVr 经验。
在 110 名受访者中，29 名（27%）遵循标准化方案。总体而言，13 名（12%）肿瘤学家对所有患者进行筛查，76 名（70%）仅对他们认为有高风险的患者进行筛查，19 名（18%）不筛查任何人。14%的受访者在其患者中经历过 HBVr。
这项调查表明，普遍的 HBV 筛查并非普遍做法，通常只有被认为有 HBVr 风险的患者才会被筛查，而这一群体并不总是能被正确识别。引入国家 HBV 筛查方案和调整荷兰肿瘤学指南可能有助于减少化疗期间的 HBVr。
